Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish

Blood

Volumn 115, Issue 16, 2010, Pages 3329-3340

  Bolli, Niccolò ^a,b   Payne, Elspeth M ^a,c   Grabher, Clemens ^a,d   Lee, Jeong Soo ^a   Johnston, Adam B ^a   Falini, Brunangelo ^b   Kanki, John P ^a   Look, A Thomas ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PERUGIA   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR; MUTANT PROTEIN; NUCLEOPHOSMIN; NUCLEOPHOSMIN 1A; NUCLEOPHOSMIN 1B; PROTEIN C MYB; PROTEIN P53; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AORTA; ARTICLE; BLOOD; BONE MARROW CELL; CELL COUNT; CELL EXPANSION; CONTROLLED STUDY; CYTOPLASM; EMBRYO; GENE EXPRESSION; GENE MUTATION; HEMATOPOIETIC CELL; HUMAN; IN VIVO STUDY; LEUKEMOGENESIS; MULTIPOTENT STEM CELL; MYELOID PROGENITOR CELL; MYELOPOIESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; STEM CELL; WILD TYPE; ZEBRA FISH;

EID: 77951474555     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-207225     Document Type: Article

References (52)

1. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer. 2006; 6(7):493-505.
2. Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol. 2004;24(3):985-996. (Pubitemid 38112164)
3. Korgaonkar C, Hagen J, Tompkins V, et al. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol. 2005;25(4): 1258-1271. (Pubitemid 40204905)
4. Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol. 2002; 4(7):529-533. (Pubitemid 34752440)
5. Wu MH, Yung BY. UV stimulation of nucleophosmin/B23 expression is an immediate-early gene response induced by damaged DNA. J Biol Chem. 2002;277(50):48234-48240.
6. Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature. 2005;437(7055):147-153. (Pubitemid 41613442)
7. Sportoletti P, Grisendi S, Majid SM, et al. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood. 2008;111(7):3859-3862.
8. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005; 352(3):254-266. (Pubitemid 40110814)
9. Liso A, Bogliolo A, Freschi V, et al. In human genome, generation of a nuclear export signal through duplication appears unique to nucleophosmin (NPM1) mutations and is restricted to AML. Leukemia. 2008;22(6):1285-1289. (Pubitemid 351833807)
10. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358(18):1909-1918. (Pubitemid 351620111)
11. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood. 2007;109(3):874-885.
12. Arber D, Brunning RD, Le Beau MM, et al. Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow SH et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer (IARC). 2008; 110-123.
13. Falini B, Bolli N, Liso A, et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia. 2009;23:1731-1743.
14. Falini B, Bolli N, Shan J, et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood. 2006;107(11):4514-4523. (Pubitemid 43801380)
15. Bolli N, Nicoletti I, De Marco MF, et al. Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. Cancer Res. 2007;67(13):6230- 6237. (Pubitemid 47037504)
16. Cheng K, Grisendi S, Clohessy JG, et al. The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence. Oncogene. 2007;26(53):7391-7400. (Pubitemid 350158712)
17. Cheng K, Sportoletti P, Ito K, et al. The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model. Blood. 2010;115(16): 3341-3345.
18. Langenau DM, Traver D, Ferrando AA, et al. Myc-induced T cell leukemia in transgenic zebrafish. Science. 2003;299(5608):887-890. (Pubitemid 36182446)
19. Bertrand JY, Traver D. Hematopoietic cell development in the zebrafish embryo. Curr Opin Hematol. 2009;16(4):243-248.
20. Payne E, Look T. Zebrafish modelling of leukaemias. Br J Haematol. 2009;146(3):247-256.
21. Detrich HW 3rd, Kieran MW, Chan FY, et al. Intraembryonic hematopoietic cell migration during vertebrate development. Proc Natl Acad Sci U S A. 1995;92(23):10713-10717.
22. Le Guyader D, Redd MJ, Colucci-Guyon E, et al. Origins and unconventional behavior of neutrophils in developing zebrafish. Blood. 2008;111(1): 132-141.
23. Bertrand JY, Kim AD, Violette EP, Stachura DL, Cisson JL, Traver D. Definitive hematopoiesis initiates through a committed erythromyeloid progenitor in the zebrafish embryo. Development. 2007;134(23):4147-4156.
24. Bertrand JY, Kim AD, Teng S, Traver D. CD41+ cmyb+ precursors colonize the zebrafish pronephros by a novel migration route to initiate adult hematopoiesis. Development. 2008;135(10): 1853-1862.
25. Hsu K, Traver D, Kutok JL, et al. The pu.1 promoter drives myeloid gene expression in zebrafish. Blood. 2004;104(5):1291-1297. (Pubitemid 39166502)
26. North TE, Goessling W, Walkley CR, et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature. 2007;447(7147): 1007-1011. (Pubitemid 46975751)
27. Lin HF, Traver D, Zhu H, et al. Analysis of thrombocyte development in CD41-GFP transgenic zebrafish. Blood. 2005;106(12):3803-3810. (Pubitemid 41739016)
28. Traver D, Paw BH, Poss KD, Penberthy WT, Lin S, Zon LI. Transplantation and in vivo imaging of multilineage engraftment in zebrafish bloodless mutants. Nat Immunol. 2003;4(12):1238-1246. (Pubitemid 37540693)
29. Zhu H, Traver D, Davidson AJ, et al. Regulation of the lmo2 promoter during hematopoietic and vascular development in zebrafish. Dev Biol. 2005;281(2):256-269. (Pubitemid 40719151)
30. Long Q, Meng A, Wang H, Jessen JR, Farrell MJ, Lin S. GATA-1 expression pattern can be recapitulated in living transgenic zebrafish using GFP reporter gene. Development. 1997;124(20):4105-4111. (Pubitemid 27483335)
31. Berghmans S, Murphey RD, Wienholds E, et al. tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci U S A. 2005;102(2):407-412. (Pubitemid 40116780)
32. Westerfield M. The zebrafish book: a guide for the laboratory use of zebrafish (Danio rerio). 4th edition. Eugene, OR: University of Oregon Press, 2000.
33. Langheinrich U, Hennen E, Stott G, Vacun G. Zebrafish as a model organism for the identification and characterization of drugs and genes affecting p53 signaling. Curr Biol. 2002;12(23):2023-2028. (Pubitemid 35450925)
34. Bennett CM, Kanki JP, Rhodes J, et al. Myelopoiesis in the zebrafish, Danio rerio. Blood. 2001; 98(3):643-651.
35. National Center for Biotechnology Information (NCBI). Mapviewer.Available at: http://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/mapview/. Accessed August 2006.
36. Barbazuk WB, Korf I, Kadavi C, et al. The syntenic relationship of the zebrafish and human genomes. Genome Res. 2000;10(9):1351-1358.
37. European Informatics Institute. Clustal W algorithm. Available at: http://www.ebi.ac.uk/Tools/clustalw2/index.html. Accessed January 2009.
38. Sidi S, Sanda T, Kennedy RD, et al. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell. 2008;133(5):864-877. (Pubitemid 351715394)
39. Gates MA, Kim L, Egan ES, et al. A genetic linkage map for zebrafish: comparative analysis and localization of genes and expressed sequences. Genome Res. 1999;9(4):334-347. (Pubitemid 29231640)
40. Robu ME, Larson JD, Nasevicius A, et al. p53 activation by knockdown technologies. PLoS Genet. 2007;3(5):e78.
41. Bolli N, De Marco MF, Martelli MP, et al. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. Leukemia. 2009;23(3):501-509.
42. Kissa K, Murayama E, Zapata A, et al. Live imaging of emerging hematopoietic stem cells and early thymus colonization. Blood. 2008;111(3): 1147-1156. (Pubitemid 351213395)
43. Thompson MA, Ransom DG, Pratt SJ, et al. The cloche and spadetail genes differentially affect hematopoiesis and vasculogenesis. Dev Biol. 1998;197(2):248-269.
44. Hall C, Flores MV, Storm T, Crosier K, Crosier P. The zebrafish lysozyme C promoter drives myeloid-specific expression in transgenic fish. BMC Dev Biol. 2007;7:42.
45. Gilley J, Fried M. One INK4 gene and no ARF at the Fugu equivalent of the human INK4A/ARF/INK4B tumour suppressor locus. Oncogene. 2001;20(50):7447-7452.
46. Kalev-Zylinska ML, Horsfield JA, Flores MV, et al. Runx1 is required for zebrafish blood and vessel development and expression of a human RUNX1-CBF2T1 transgene advances a model for studies of leukemogenesis. Development. 2002;129(8):2015-2030.
47. Liu TX, Rhodes J, Deng M, et al. Dominant-interfering C/EBPalpha stimulates primitive erythropoiesis in zebrafish. Exp Hematol. 2007;35(2): 230-239.
48. Yeh JR, Munson KM, Elagib KE, Goldfarb AN, Sweetser DA, Peterson RT. Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. Nat Chem Biol. 2009;5(4):236-243.
49. Burns CE, Galloway JL, Smith AC, et al. A genetic screen in zebrafish defines a hierarchical network of pathways required for hematopoietic stem cell emergence. Blood. 2009;113(23):5776-5782.
50. Martelli MP, Pettirossi V, Bonifacio E, et al. Evidence for CD34+ hematopoietic progenitor cell involvement in acute myeloid leukemia with NPM1 gene mutation: implications for the cell of origin [abstract]. Blood. 2008;112(11):Abstract 307.
51. Taussig DC, Vargaftig J, Miraki-Moud F, et al. Leukemia initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34- fraction. Blood. 2010;115(10): 1976-1984.
52. Pasqualucci L, Liso A, Martelli MP, et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. Blood. 2006;108(13):4146-4155.